In 2022, 8.3 million maria cases were reported in Burkina Faso. Since 2014, seasonal malaria chemoprevention (SMC), using antimalarial medicines sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ), has been implemented. However, there are no data on molecular resistance markers for these drugs. This study assessed resistance to SP and AQ by examining specific molecular markers in blood samples from the Boussé district before and after SMC in 2022. This poster was presented at the 72nd annual meeting of the American Society of Tropical Medicine and Hygiene.
Country: Burkina FasoKeywords: ASTMH | Malaria | Resistance management | SMC
« Back to Publications